432 related articles for article (PubMed ID: 36755812)
21. Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.
Gujar S; Pol JG; Kim Y; Lee PW; Kroemer G
Trends Immunol; 2018 Mar; 39(3):209-221. PubMed ID: 29275092
[TBL] [Abstract][Full Text] [Related]
22. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them.
Hu PY; Fan XM; Zhang YN; Wang SB; Wan WJ; Pan HY; Mou XZ
Appl Microbiol Biotechnol; 2020 Oct; 104(19):8231-8242. PubMed ID: 32816087
[TBL] [Abstract][Full Text] [Related]
23. Computer-aided designing of oncolytic viruses for overcoming translational challenges of cancer immunotherapy.
Lathwal A; Kumar R; Raghava GPS
Drug Discov Today; 2020 Jul; 25(7):1198-1205. PubMed ID: 32344041
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives.
Guo ZS; Liu Z; Kowalsky S; Feist M; Kalinski P; Lu B; Storkus WJ; Bartlett DL
Front Immunol; 2017; 8():555. PubMed ID: 28555136
[TBL] [Abstract][Full Text] [Related]
25. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic viruses as immunotherapy: progress and remaining challenges.
Aurelian L
Onco Targets Ther; 2016; 9():2627-37. PubMed ID: 27226725
[TBL] [Abstract][Full Text] [Related]
27. Virotherapy: From single agents to combinatorial treatments.
Malfitano AM; Di Somma S; Iannuzzi CA; Pentimalli F; Portella G
Biochem Pharmacol; 2020 Jul; 177():113986. PubMed ID: 32330494
[TBL] [Abstract][Full Text] [Related]
28. Immune System, Friend or Foe of Oncolytic Virotherapy?
Filley AC; Dey M
Front Oncol; 2017; 7():106. PubMed ID: 28589085
[TBL] [Abstract][Full Text] [Related]
29. Genetic modification of oncolytic viruses to enhance antitumor immunity.
Davola ME; Vito A; Wei J; El-Sayes N; Workenhe S; Mossman KL
Methods Enzymol; 2020; 635():231-250. PubMed ID: 32122548
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic Immunotherapy for Treatment of Cancer.
Tsun A; Miao XN; Wang CM; Yu DC
Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
[TBL] [Abstract][Full Text] [Related]
31. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
Wei D; Xu J; Liu XY; Chen ZN; Bian H
Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic viruses and their application to cancer immunotherapy.
Chiocca EA; Rabkin SD
Cancer Immunol Res; 2014 Apr; 2(4):295-300. PubMed ID: 24764576
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in oncolytic virus-based cancer therapy.
Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
[TBL] [Abstract][Full Text] [Related]
34. Determinants of the efficacy of viro-immunotherapy: A review.
de Graaf JF; Huberts M; Fouchier RAM; van den Hoogen BG
Cytokine Growth Factor Rev; 2020 Dec; 56():124-132. PubMed ID: 32919831
[TBL] [Abstract][Full Text] [Related]
35. The inducers of immunogenic cell death for tumor immunotherapy.
Li X
Tumori; 2018; 104(1):1-8. PubMed ID: 28967094
[TBL] [Abstract][Full Text] [Related]
36. The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
Workenhe ST; Verschoor ML; Mossman KL
Future Oncol; 2015; 11(4):675-89. PubMed ID: 25686121
[TBL] [Abstract][Full Text] [Related]
37. A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy.
Bahreyni A; Liu H; Mohamud Y; Xue YC; Fan YM; Zhang YL; Luo H
BMC Med; 2023 May; 21(1):193. PubMed ID: 37226233
[TBL] [Abstract][Full Text] [Related]
38. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments.
Inoue H; Tani K
Cell Death Differ; 2014 Jan; 21(1):39-49. PubMed ID: 23832118
[TBL] [Abstract][Full Text] [Related]
39. Microbes mediated immunogenic cell death in cancer immunotherapy.
Huang J; Duan F; Xie C; Xu J; Zhang Y; Wang Y; Tang YP; Leung EL
Immunol Rev; 2024 Jan; 321(1):128-142. PubMed ID: 37553793
[TBL] [Abstract][Full Text] [Related]
40. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies.
Workenhe ST; Mossman KL
Mol Ther; 2014 Feb; 22(2):251-256. PubMed ID: 24048442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
